HENDERSON, NV / ACCESSWIRE / October 15, 2018 / A fascinating biotechnology firm PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in the between late August and early September going from a low of $0.0039 to a high of over $0.28, the stock is still holding a substantial gain of 1795% as of the close on Friday. PPCB may start receiving increased attention from the street at any moment. PPCB has a 52 week high of $0.77. PPCB is currently readying for its Phase 1 Clinical Trial of its lead product PRP, which was granted FDA Orphan Drug Designation for Pancreatic cancer. If this is the first time you are hearing about PPCB, start doing your own research now. PPCB is an impressive biotech firm, with an intriguing patent portfolio. Those that find PPCB before its clinical trial could be in store for a great ride.
Propanc Biopharma, Inc. (PPCB)
Market Cap: $18.65M Share Price: $0.118
Propanc Biopharma, Inc. is a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers, today the company announced the execution of a research collaboration agreement with the University of Jaén, Spain, for the provision of research services and scientific technical advice for the Company's POP1 drug discovery program. The company stated the goal for the program is to synthesize and develop a backup clinical compound to the Company's lead product candidate, PRP. The development of the backup compound will be used for treating patients with limited therapeutic options for the treatment of solid tumors.
Aurora Cannabis (ACBFF)
Market Cap: $8.72B Share Price: $10.10
Aurora Cannabis has applied to be listed on the NYSE. This is a very positive development for the company, and its shareholders.
Aphria, Inc. (APHQF)
Market Cap: $3.26B Share Price: $14.13
Aphria Inc. (APHQF) announced closing the acquisition of LATAM Holdings Inc. from Scythian Biosciences (SCCYF). The Transaction was funded by the assumption of US$1 million of existing LATAM Holdings debt with the remaining consideration funded by the issuance of 15,678,310 common shares of Aphria. The closing was pursuant to the terms of the definitive share purchase agreement previously announced by the Company on July 17, 2018.
Amarin Corporation plc (AMRN)
Market Cap: $4.22B Share Price: $14.35
Amarin reported that its highly refined fish oil pill Vascepa provided a significant cardiovascular benefit in patients with elevated triglyceride levels, despite being on statin therapy. Leading up to this top-line data readout, however, almost no one outside the company thought that Vascepa had a realistic shot at producing such a pronounced clinical benefit in this landmark cardiovascular outcomes trial.
Important Disclaimer, Please Read:
The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.
The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.
Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company.
PPCB has paid, and continues to pay Regal to disseminate truthful and potentially material information regarding PPCB.
Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.
Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.
Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in PPCB can be found updated here: http://www.regalconsultingllc.com/disclaimer/.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and ninety-two thousand two hundred dollars total by Regal Consulting. LLC, for news commentary articles for PPCB. PPCB and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of PPCB in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting. LLC,For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communication, LLC